SS-31
Elamipretide (D-Arg-Dmt-Lys-Phe-NH2)
SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane to optimize mitochondrial structure and function. Originally developed for mitochondrial diseases and heart failure, SS-31 enhances cellular energy production and reduces oxidative stress across multiple organ systems. It has shown promise in clinical trials for heart failure with preserved ejection fraction, Barth syndrome, and mitochondrial myopathies.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
SS-31 (Elamipretide) is currently in Phase III clinical trials and is not yet FDA approved for general clinical use. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all investigational uses.